These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33423554)

  • 1. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.
    Chakraborty C; Bhattacharya M; Mallick B; Sharma AR; Lee SS; Agoramoorthy G
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):225-238. PubMed ID: 33423554
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies.
    Seyedpour S; Khodaei B; Loghman AH; Seyedpour N; Kisomi MF; Balibegloo M; Nezamabadi SS; Gholami B; Saghazadeh A; Rezaei N
    J Cell Physiol; 2021 Apr; 236(4):2364-2392. PubMed ID: 32901936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
    Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
    ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment Strategies.
    Kumawat P; Agarwal LK; Sharma K
    Curr Microbiol; 2024 May; 81(7):169. PubMed ID: 38733424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential inhibitors of SARS-CoV-2: recent advances.
    Jamalipour Soufi G; Iravani S
    J Drug Target; 2021 Apr; 29(4):349-364. PubMed ID: 33210953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
    Nayak SK
    Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.
    Zhuo LS; Wang MS; Yang JF; Xu HC; Huang W; Shang LQ; Yang GF
    Top Curr Chem (Cham); 2021 Apr; 379(3):23. PubMed ID: 33886017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the SARS-CoV-2-host protein interaction network reveals new biology and drug candidates: focus on the spike surface glycoprotein and RNA polymerase.
    Sokullu E; Pinard M; Gauthier MS; Coulombe B
    Expert Opin Drug Discov; 2021 Aug; 16(8):881-895. PubMed ID: 33769912
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding Severe Acute Respiratory Syndrome Coronavirus 2 Replication to Design Efficient Drug Combination Therapies.
    Ortega JT; Zambrano JL; Jastrzebska B; Liprandi F; Rangel HR; Pujol FH
    Intervirology; 2020; 63(1-6):2-9. PubMed ID: 33099545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
    Ribone SR; Paz SA; Abrams CF; Villarreal MA
    J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.
    Wang R; Stephen P; Tao Y; Zhang W; Lin SX
    Biomed Pharmacother; 2021 May; 137():111232. PubMed ID: 33486202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reactive Centre Loop Mutagenesis of SerpinB3 to Target TMPRSS2 and Furin: Inhibition of SARS-CoV-2 Cell Entry and Replication.
    Singh S; O'Reilly S; Gewaid H; Bowie AG; Gautier V; Worrall DM
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
    Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
    Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
    Gupta VK; Murthy MK; Patil S
    Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of the anti-SARS-CoV-2 properties of Artemisia annua, its antiviral action, protein-associated mechanisms, and repurposing for COVID-19 treatment.
    Fuzimoto AD
    J Integr Med; 2021 Sep; 19(5):375-388. PubMed ID: 34479848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.